Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...
About WU-CART-007 WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to ...
A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is ...
Please provide your email address to receive an email when new articles are posted on . A sequential CAR-T and HSCT regimen did not need preconditioning or GVHD prophylaxis to confer remission for CD7 ...
ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in ...
A new type of allogeneic CAR-T cell immunotherapy that targets aggressive blood cancers has shown promising results alongside manageable side effects, according to the results of an international ...
-- First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 -- The Global Study Will Evaluate WU-CART-007 in Pediatric and Adult Patients ST.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results